Clinical trials in Venezuela run $3,000–$8,000 per patient — already published on this hub — depending on indication, study complexity, and monitoring. Headline ~40% faster and ~30% lower program cost versus typical US/EU baselines is bioaccess® experience since 2010, not a formal study. INHRR's 2025 fee schedule puts Phase I–III clinical-trial registration at approximately VES 52,612.41 per protocol, subject to periodic adjustment. We run trials there — and we budget them in USD equivalents for international sponsors.
This hub already publishes $3,000–$8,000 per patient for clinical trials in Venezuela, depending on indication, study complexity, and monitoring. Those are among the lowest figures bioaccess® publishes in Latin America — and they sit inside full-service CRO scope: INHRR submission, ethics coordination, site contracting, monitoring with source data verification, and safety reporting.